04.22.25 -- How To Approach Tech Transfers And Sponsored Life Sciences Research In AI

Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.

Partnering with a CDMO that offers comprehensive and robust E&L studies can help facilitate a smooth product launch by ensuring minimal impact from impurities, all while mitigating risks.

Here, we highlight the discovery of diverse and potent human mAbs targeting two tumor antigens, showcasing their potential to enhance CAR-T cell therapies across various cancers.

Efficiency in bioprocessing and achieving rapid mixing across various viscosities is crucial for consistent biopharmaceutical product quality. Discover more about the benefits of this mixer.

Kimberly Shepard, Ph.D., principal engineer in R&D, addresses the challenges associated with spray-drying late-stage lung cancer treatments, including proteins, peptides, and mAbs.